Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC&C Group Regulatory News (CCR)

Share Price Information for C&C Group (CCR)

Share Price is delayed by 15 minutes
Get Live Data
94.50    2.30 (2.49%)
Bid:
94.10
Ask:
94.40
Spread: 0.30 (0.319%)
Market Cap: £348.08m
CCR Live PriceLast checked at - London Stock Exchange

Intraday C&C Group Share Chart

PY Accounting Adjustments and Directorate Changes

7 Jun 2024 07:00

RNS Number : 4994R
C&C Group Plc
07 June 2024
 

Prior Year Accounting Adjustments and Directorate Changes

  

This announcement contains inside information.

 

Dublin, London 7 June 2024: C&C Group plc ('C&C' or the 'Group') announces that, as reflected in the financial update RNS released this morning, prior year accounting adjustments are expected to be made in respect of inventory and balance sheet items. There is no change to the Group's expected earnings for FY24-FY27, however they do impact previously reported financial statements as summarised below.

 

Prior Year Accounting Adjustments

These adjustments in aggregate represent an underlying operating profit adjustments charge of 5m. By year, the restatements comprised a 1m adjustment charge in FY2023, a 3m adjustment credit in FY2022 and a 7m adjustment charge in FY2021. In addition, the Group is expecting to record an exceptional prior year (FY2023) charge with respect to onerous apple contracts of €12m which was initially expected to be recorded in FY2024. The total value of the adjustments (underlying plus exceptional) is €17m. There will clearly also be an impact on the unaudited FY2024 Interim Results, details of which will be set out in the FY2025 Interim Results in October.

These adjustments relate principally to five items, inventory related matters at Clonmel (10m charge), goods received not invoiced ("GRNI") (€3m credit), the timing of release of customer discount liabilities (3m credit), change in accounting treatment of glassware (€1m charge) together with additional items (net €nil) over the three-year period in question. These adjustments are set out in more detail in the Summary of FY2024 Financial Performance (Unaudited) update announcement released separately this morning. Neither that announcement, nor the financial information set out in this announcement, is, nor is it intended to be, a preliminary statement of annual results given they each contain unaudited financial information which has not been agreed with the auditors as would be required for a preliminary statement of annual results.

 

The adjustments have been made following detailed internal and external reviews of inventory and balance sheet reconciliations after discrepancies were notified to the Audit Committee earlier this year. An independent accounting firm was appointed to investigate the relevant issues and to determine any potential financial impact and the time period over which the issues extended. The issues that were identified were then considered in detail by both the Group's Audit Committee (the 'Committee') and the Board, as part of the finalisation of the Group's FY2024 Annual Report and Accounts.

 

The Board and Audit Committee have considered the background to these items in detail, including representations and accuracy of information provided to the external auditors and to the Committee and the Board at the time the items arose and in subsequent financial years. In addition to accounting mistakes and errors of judgement underlying these historic issues, it is clear from the reviews undertaken that there were failures in the Group's reporting framework and that in parts of the organisation behaviours fell short of the levels of transparency demanded and required such that opportunities were missed to identify and appropriately address the relevant issues. Further details relating to the underlying issues and the consequent actions and improvements to the controls and governance frameworks that have been and are being taken to ensure that there is no repetition of these issues will be set out within the Group Audited Annual Report and Accounts which is expected to be issued before the end of June 2024 and the Board will also ensure that the Company complies with all related legal and regulatory requirements.

Directorate Changes

The Group's Chief Executive Officer, Patrick McMahon, was Chief Financial Officer during the periods to which these adjustments relate and acknowledges that the relevant shortcomings occurred at a time when he had overall responsibility for the Group's finance function. Accordingly, he has informed the Board that he will step down as CEO and as a director with immediate effect. The Board, with regret, has agreed that it would be in the best interests of the Group for Patrick to do so. It has been agreed that he will remain as an employee until the end of September to facilitate a smooth transition. The Group thanks Patrick for his contribution and service over many years.

In addition to his duties as Chair of the Board, Ralph Findlay has been appointed Group CEO with immediate effect to ensure continuity of executive leadership. It is expected that he will remain in post as Group CEO for between 12 and 18 months, subject to the timing of the recruitment of Patrick's long-term successor with the relevant search to commence in the autumn. 

 

In light of his appointment as Group CEO, Ralph Findlay has stepped down as Chair of the Nomination Committee and the Senior Independent Director, Chris Browne, has been appointed Chair of the Nomination Committee with immediate effect.

 

Executive Arrangements

 

All remuneration arrangements for Ralph Findlay are consistent with the terms of the Directors' Remuneration Policy approved by shareholders at the AGM in July 2021 (the 'Policy'). As Group CEO, Ralph Findlay will receive an annual base salary of €702k, a pension allowance of 5% of salary in line with the contribution available for the Group's employees, a benefit allowance of 7.5% of salary and maximum annual bonus opportunity of 125% of salary.

 

Patrick McMahon's remuneration and severance terms will be in line with his service agreement and the Policy.

 

END

 

 

 

Contacts

 

C&C Group plc

Email: investor.relations@candcgroup.ie

 

Investors, Analysts & Media

 

FTI Consulting

Jonathan Neilan / Paddy Berkery

Tel: +353 86 231 4135 / +353 86 6025988

Email: CandCGroup@fticonsulting.com

 

About C&C Group plc

C&C Group plc is a leading, vertically integrated premium drinks company which manufactures, markets and distributes branded beer, cider, wine, spirits, and soft drinks across the UK and Ireland.

· C&C Group's portfolio of owned/exclusive brands include Bulmers, the leading Irish cider brand and Tennent's, the leading Scottish beer brand; as well as a range of fast-growing, premium and craft ciders and beers, such as Heverlee, Menabrea, Five Lamps and Orchard Pig. C&C exports its Magners and Tennent's brands to over 40 countries worldwide.

· C&C Group has owned brand and contract manufacturing/packing operations in Co. Tipperary, Ireland and Glasgow, Scotland.

· C&C is the No.1 drinks distributor to the UK and Ireland hospitality sectors. Operating through the Matthew Clark, Bibendum, Tennent's and Bulmers Ireland brands, the Group has a market leading range, scale and reach including an intimate understanding of the markets it serves. Together this provides a key route-to-market for major international beverage companies.

 

C&C Group plc is an Irish incorporated FTSE 250 company headquartered in Dublin and is listed on the London Stock Exchange.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRQKABBDBKBDAK
Date   Source Headline
3rd Jun 20263:59 pmRNSHolding(s) in Company
2nd Jun 20265:19 pmRNSHolding(s) in Company
2nd Jun 202612:04 pmRNSHolding(s) in Company
1st Jun 20266:18 pmRNSTotal Voting Rights
28th May 20264:30 pmRNSHolding(s) in Company
28th May 202610:40 amRNSDirector/PDMR Shareholding
27th May 20264:43 pmRNSHolding(s) in Company
19th May 20263:54 pmRNSDirector/PDMR Shareholding
19th May 20267:00 amRNSFinal Results
8th May 20267:00 amRNSHolding(s) in Company
7th May 20265:28 pmRNSHolding(s) in Company
1st May 20264:28 pmRNSHolding(s) in Company
1st May 20264:25 pmRNSTotal Voting Rights
30th Apr 20264:49 pmRNSHolding(s) in Company
29th Apr 202611:14 amRNSHolding(s) in Company
29th Apr 202611:05 amRNSHolding(s) in Company
16th Apr 20264:37 pmRNSDirector/PDMR Shareholding
9th Apr 202612:12 pmRNSChief Financial Officer Update
1st Apr 202611:58 amRNSTotal Voting Rights
20th Mar 20265:42 pmRNSBoard Committee Membership Update
17th Mar 20263:30 pmRNSDirector/PDMR Shareholding
13th Mar 202612:33 pmRNSHolding(s) in Company
6th Mar 20261:15 pmRNSAcquisition of Innis & Gunn Brand
2nd Mar 202611:31 amRNSTotal Voting Rights
24th Feb 20261:09 pmRNSDirectorate change
18th Feb 202611:56 amRNSDirector/PDMR Shareholding
6th Feb 202612:34 pmRNSDirector/PDMR Shareholding
5th Feb 20267:02 amRNSAppointment of Chief Financial Officer
2nd Feb 202612:55 pmRNSTotal Voting Rights
23rd Jan 20267:00 amRNSFY26 Trading Update
19th Jan 20265:26 pmRNSDirector/PDMR Shareholding
9th Jan 20263:21 pmRNS2025 AGM Voting Update Statement
5th Jan 202611:40 amRNSTotal Voting Rights
23rd Dec 20255:53 pmRNSDirector/PDMR Shareholding
23rd Dec 20255:53 pmRNSDirector/PDMR Shareholding
22nd Dec 20251:12 pmRNSHolding(s) in Company
22nd Dec 20251:12 pmRNSHolding(s) in Company
17th Dec 202512:36 pmRNSDirector/PDMR Shareholding
17th Dec 202512:36 pmRNSDirector/PDMR Shareholding
10th Dec 20256:08 pmRNSHolding(s) in Company
1st Dec 20253:27 pmRNSTotal Voting Rights
26th Nov 202511:40 amRNSHolding(s) in Company
24th Nov 20254:38 pmRNSHolding(s) in Company
19th Nov 20254:46 pmRNSDirector/PDMR Shareholding
19th Nov 202510:45 amRNSDirector/PDMR Shareholding
18th Nov 20253:30 pmRNSDirector/PDMR Shareholding
14th Nov 202511:19 amRNSHolding(s) in Company
13th Nov 20251:45 pmRNSHolding(s) in Company
3rd Nov 20253:09 pmRNSTotal Voting Rights
28th Oct 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.